ISOPHRA

Active substance: Framicetin
ATX Code: R01AX08
KFH: Antibacterial drug for topical application in ENT practice
ICD-10 codes (readings): J00, J01, J31, J32, Z29.2, Z29.8
CFU Code: 06.05.04
Manufacturer: Laboratoires BOUCHARA-RECORDATI (France)

DRUGS FORM, COMPOSITION AND PACKAGING

Spray nasal 1.25%1 ml
framicetin sulfate12.5 mg (8 thousand IU)

Excipients: methyl parahydroxybenzoate, sodium chloride, citric acid, distilled water.

15 ml - polyethylene bottles (1) complete with a spray - packs cardboard.

 

PHARMACHOLOGIC EFFECT

Antibiotic from the group of aminoglycosides for topical application in otorhinolaryngology. It is bactericidal. Active with respect to Gram-positive and gram-negative bacteria that cause the development of infectious processes in the upper respiratory tract.

 

PHARMACOKINETICS

Studies of the pharmacokinetics of the preparation of Isophra have not been carried out due to low systemic absorption.

 

INDICATIONS

As part of combination therapy for infectious and inflammatory diseases of the upper respiratory tract, including:

- rhinitis;

- Rhinopharyngitis;

- sinusitis (in the absence of damage to the septum);

Preventive maintenance and treatment of inflammatory processes after surgical interventions.

 

DOSING MODE

Adults Assign an 1 injection to each nostril 4-6 times / day.

Children prescribe by 1 injection into each nostril 3 times / day.

The average duration of therapy is 7 days.

When using the bottle should be kept in a vertical position.

 

SIDE EFFECT

Allergic reactions: in single cases - skin manifestations.

 

CONTRAINDICATIONS

- Hypersensitivity to framicetin and other antibiotics from the group of aminoglycosides.

 

PREGNANCY AND LACTATION

Adequate and strictly controlled clinical studies of the safety of the use of Isofra during pregnancy and lactation (breastfeeding) were not carried out.

 

SPECIAL INSTRUCTIONS

If the therapeutic effect is absent or weak during the course of 7 days of treatment, the drug must be discontinued.

 

OVERDOSE

Due to the low degree of absorption in the systemic blood flow, an overdose is unlikely.

 

DRUG INTERACTION

Clinically significant interactions of the preparation with other medicines have not been identified.

 

TERMS OF RELEASE FROM PHARMACY

The drug is released by prescription.

 

TERMS AND CONDITIONS OF STORAGE

The drug should be stored at a temperature not higher than 25 ° C. Shelf life is 3 years.